论文部分内容阅读
为了比较晚期卵巢癌妇女细胞减灭术前施行新辅助化疗和传统的减灭术后应用细胞毒化疗(常规组)两者的无瘤生存(progression-free survival)和总生存率,Yale-New Haven医疗中心回顾性研究了1979～1996年间59例诊断患有晚期卵巢癌而施行以铂类为主的新辅助化疗的患者,通过体格检查、CT扫描和细胞学或组织学检查确定诊断。并与206例Ⅲ期或Ⅳ期卵巢癌先行细胞减灭术然后以铂类为主联合化疗的常规组进行对照分析。 新辅助化疗组接受以铂类为主的联合化疗(顺
In order to compare progression-free survival and overall survival of neoplastic ovarian cancer patients treated with neoadjuvant chemotherapy prior to cytoreductive surgery with conventional cytotoxic chemotherapy (conventional group), Yale-New Haven Medical Center retrospectively reviewed 59 patients diagnosed with advanced ovarian cancer from 1979 to 1996 who underwent neoadjuvant chemotherapy predominantly of platinum and were diagnosed by physical examination, CT scan and cytology or histology. And with 206 cases of stage Ⅲ or Ⅳ ovarian cancer cytoreductive surgery and platinum-based chemotherapy in the conventional group control analysis. Neoadjuvant chemotherapy group received platinum-based combination chemotherapy (cis